{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:13:35Z","timestamp":1768702415161,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00228-025-03829-3","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T11:26:36Z","timestamp":1743765996000},"page":"815-830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of pembrolizumab in the treatment of advanced hepatocellular carcinoma: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"81","author":[{"given":"Mingyang","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"3","key":"3829_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3829_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS (2021) Hepatocellular carcinoma. Nat Rev Dis Prim 7(1):6","journal-title":"Nat Rev Dis Prim"},{"issue":"2","key":"3829_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.hbpd.2021.12.004","volume":"21","author":"ZW Tao","year":"2022","unstructured":"Tao ZW, Cheng BQ, Zhou T, Gao YJ (2022) Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: a narrative review. Hepatobiliary Pancreat Dis Int 21(2):134\u2013144","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"11","key":"3829_CR4","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.3390\/jpm12111788","volume":"12","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Ricci AD, Brandi G (2022) Trans-arterial chemoembolization plus systemic treatments for hepatocellular carcinoma: an update. J Pers Med 12(11):1788","journal-title":"J Pers Med"},{"issue":"15","key":"3829_CR5","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.23.02745","volume":"42","author":"JD Gordan","year":"2024","unstructured":"Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, Goff L, Gupta S, Guy J, Hoang HT et al (2024) Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J Clin Oncol 42(15):1830\u20131850","journal-title":"J Clin Oncol"},{"issue":"10126","key":"3829_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163\u20131173","journal-title":"Lancet"},{"key":"3829_CR7","unstructured":"FDA approves lenvatinib for unresectable hepatocellular carcinoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lenvatinib-unresectable-hepatocellular-carcinoma. Accessed 18 Mar 2025"},{"key":"3829_CR8","unstructured":"Regorafenib. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/regorafenib. Accessed 18 Mar 2025"},{"key":"3829_CR9","unstructured":"FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-fda-approval-cabozantinib-hepatocellular-carcinoma. Accessed 18 Mar 2025"},{"issue":"19","key":"3829_CR10","doi-asserted-by":"publisher","first-page":"11363","DOI":"10.3390\/ijms231911363","volume":"23","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Ricci AD (2022) Challenges and future trends of hepatocellular carcinoma immunotherapy. Int J Mol Sci 23(19):11363","journal-title":"Int J Mol Sci"},{"issue":"10088","key":"3829_CR11","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling THR et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389(10088):2492\u20132502","journal-title":"Lancet"},{"issue":"7","key":"3829_CR12","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19(7):940\u2013952","journal-title":"Lancet Oncol"},{"issue":"20","key":"3829_CR13","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894\u20131905","journal-title":"N Engl J Med"},{"key":"3829_CR14","unstructured":"FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma. Accessed 18 Mar 2025"},{"key":"3829_CR15","doi-asserted-by":"crossref","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Van Dao T, De Toni EN et al (2022)\u00a0Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 1(8):EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070"},{"key":"3829_CR16","unstructured":"FDA approves tremelimumab in combination with durvalumab for unresectable hepatocellular carcinoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tremelimumab-combination-durvalumab-unresectable-hepatocellular-carcinoma. Accessed 18 Mar 2025"},{"issue":"17","key":"3829_CR17","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.3390\/cancers14174142","volume":"14","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Mollica V, Marchetti A, Nuvola G, Rosellini M, Tassinari E, Molina-Cerrillo J, Myint ZW, Buchler T, Monteiro FSM et al (2022) Adjuvant PD-1 and PD-L1 inhibitors and relapse-free survival in cancer patients: the MOUSEION-04 study. Cancers (Basel) 14(17):4142","journal-title":"Cancers (Basel)"},{"issue":"11","key":"3829_CR18","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","volume":"12","author":"G Kwok","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL (2016) Pembrolizumab (keytruda). Hum Vaccin Immunother 12(11):2777\u20132789","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"3829_CR19","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington KJ, Burtness B, Greil R, Souli\u00e8res D, Tahara M, de Castro G, Jr., Psyrri A, Brana I, Bast\u00e9 N, Neupane P, et al (2023) Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol 41(4):790\u2013802","journal-title":"J Clin Oncol"},{"issue":"10","key":"3829_CR20","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J et al (2020) Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 6(10):1571\u20131580","journal-title":"JAMA Oncol"},{"issue":"24","key":"3829_CR21","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1200\/JCO.22.01599","volume":"41","author":"C Robert","year":"2023","unstructured":"Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A et al (2023) Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma. J Clin Oncol 41(24):3998\u20134003","journal-title":"J Clin Oncol"},{"issue":"9","key":"3829_CR22","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810\u2013821","journal-title":"N Engl J Med"},{"issue":"21","key":"3829_CR23","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Cs\u0151szi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC et al (2020) Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol 38(21):2369\u20132379","journal-title":"J Clin Oncol"},{"issue":"7","key":"3829_CR24","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1200\/JCO.22.00620","volume":"41","author":"S Qin","year":"2023","unstructured":"Qin S, Chen Z, Fang W, Ren Z, Xu R, Ryoo BY, Meng Z, Bai Y, Chen X, Liu X et al (2023) Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase III trial. J Clin Oncol 41(7):1434\u20131443","journal-title":"J Clin Oncol"},{"issue":"11","key":"3829_CR25","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.3390\/pharmaceutics14112263","volume":"14","author":"HY Kuo","year":"2022","unstructured":"Kuo HY, Han MZ, Liao CH, Lin YJ, Wang CT, Chen SH, Chang TT, Chen PJ, Lin SH, Chen CY et al (2022) Real-world comparative effectiveness of nivolumab versus pembrolizumab in patients with unresectable hepatocellular carcinoma. Pharmaceutics 14(11):2263","journal-title":"Pharmaceutics"},{"issue":"1","key":"3829_CR26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1186\/s12885-023-11298-z","volume":"23","author":"YH Chen","year":"2023","unstructured":"Chen YH, Tsai CH, Chen YY, Wang CC, Wang JH, Hung CH, Kuo YH (2023) Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma. BMC Cancer 23(1):810","journal-title":"BMC Cancer"},{"key":"3829_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.751159","volume":"11","author":"X Huang","year":"2021","unstructured":"Huang X, Xu L, Ma T, Yin X, Huang Z, Ran Y, Ni Y, Bi X, Che X (2021) Lenvatinib plus immune checkpoint inhibitors improve survival in advanced hepatocellular carcinoma: a retrospective study. Front Oncol 11:751159","journal-title":"Front Oncol"},{"issue":"10","key":"3829_CR28","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/apt.15245","volume":"49","author":"B Scheiner","year":"2019","unstructured":"Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, Koch S, Schwabl P, Hinrichs JB, Waneck F et al (2019) Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther 49(10):1323\u20131333","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"3829_CR29","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00520-023-08083-w","volume":"31","author":"DC Guven","year":"2023","unstructured":"Guven DC, Erul E, Kaygusuz Y, Akagunduz B, Kilickap S, De Luca R, Rizzo A (2023) Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support Care Cancer 31(12):624","journal-title":"Support Care Cancer"},{"key":"3829_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"20","key":"3829_CR31","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.3390\/cancers16203458","volume":"16","author":"YC Hsu","year":"2024","unstructured":"Hsu YC, Lin PT, Teng W, Hsieh YC, Chen WT, Su CW, Wang CT, Chai PM, Lin CC, Lin CY et al (2024) (2024) Comparing lenvatinib\/pembrolizumab with atezolizumab\/bevacizumab in unresectable hepatocellular carcinoma: a real-world experience with propensity score matching analysis. Cancers (Basel) 16(20):3458","journal-title":"Cancers (Basel)"},{"issue":"4","key":"3829_CR32","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan M, Gane EJ, Marron TU, Perales-Linares R, Yan J, Cooch N, Shu DH, Fertig EJ, Kagohara LT, Bartha G et al (2024) Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat Med 30(4):1044\u20131053","journal-title":"Nat Med"},{"issue":"4","key":"3829_CR33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1159\/000529636","volume":"12","author":"P Merle","year":"2023","unstructured":"Merle P, Kudo M, Edeline J, Bouattour M, Cheng AL, Chan SL, Yau T, Garrido M, Knox J, Daniele B et al (2023) Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: longer term follow-up from the phase 3 KEYNOTE-240 trial. Liver Cancer 12(4):309\u2013320","journal-title":"Liver Cancer"},{"key":"3829_CR34","doi-asserted-by":"crossref","unstructured":"Kudo M, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer DH, Verslype C, Zagonel V, Fartoux L, Vogel A et al (2022)\u00a0Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer (Oxford, England : 1990) 167:1\u201312","DOI":"10.1016\/j.ejca.2022.02.009"},{"issue":"1","key":"3829_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-021-00995-8","volume":"14","author":"JY Hong","year":"2022","unstructured":"Hong JY, Cho HJ, Sa JK, Liu X, Ha SY, Lee T, Kim H, Kang W, Sinn DH, Gwak GY et al (2022) Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Med 14(1):1","journal-title":"Genome Med"},{"issue":"9","key":"3829_CR36","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/00365521.2020.1794539","volume":"55","author":"R Mahn","year":"2020","unstructured":"Mahn R, Vogt A, Kupczyk P, Sadeghlar F, van Beekum K, H\u00fcneburg R, Meyer C, Toma M, Ahmadzadehfar H, Essler M et al (2020) Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience. Scand J Gastroenterol 55(9):1057\u20131062","journal-title":"Scand J Gastroenterol"},{"issue":"11","key":"3829_CR37","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1007\/s00262-022-03185-6","volume":"71","author":"CJ Wu","year":"2022","unstructured":"Wu CJ, Lee PC, Hung YW, Lee CJ, Chi CT, Lee IC, Hou MC, Huang YH (2022) Lenvatinib plus pembrolizumab for systemic therapy-na\u00efve and -experienced unresectable hepatocellular carcinoma. Cancer immunology, immunotherapy\u202f: CII 71(11):2631\u20132643","journal-title":"Cancer immunology, immunotherapy : CII"},{"issue":"12","key":"3829_CR38","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.3390\/biomedicines10123202","volume":"10","author":"D T\u00fcmen","year":"2022","unstructured":"T\u00fcmen D, Heumann P, G\u00fclow K, Demirci CN, Cosma LS, M\u00fcller M, Kandulski A (2022) Pathogenesis and current treatment strategies of hepatocellular carcinoma. Biomedicines 10(12):3202","journal-title":"Biomedicines"},{"issue":"15","key":"3829_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025180","volume":"100","author":"J Chen","year":"2021","unstructured":"Chen J, Wang J, Xu H (2021) Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: a systematic review and network meta-analysis. Medicine (Baltimore) 100(15):e25180","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"3829_CR40","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1186\/s12885-024-13127-3","volume":"24","author":"A Zafar","year":"2024","unstructured":"Zafar A, Rashid AA, Moeed A, Tahir MJ, Khan AJ, Shrateh ON, Ahmed A (2024) Safety and efficacy of PD-1\/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis. BMC Cancer 24(1):1353","journal-title":"BMC Cancer"},{"issue":"21","key":"3829_CR41","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.3390\/cancers16213689","volume":"16","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, Ayasun R, Rizzo A (2024) Guven DC (2024) Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: a systematic review and meta-analysis. Cancers (Basel) 16(21):3689","journal-title":"Cancers (Basel)"},{"key":"3829_CR42","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2147\/JHC.S455612","volume":"11","author":"G Shao","year":"2024","unstructured":"Shao G, Ma Y, Qu C, Gao R, Zhu C, Qu L, Liu K, Li N, Sun P, Cao J (2024) Machine learning model based on the neutrophil-to-eosinophil ratio predicts the recurrence of hepatocellular carcinoma after surgery. J Hepatocell Carcinoma 11:679\u2013691","journal-title":"J Hepatocell Carcinoma"},{"issue":"8","key":"3829_CR43","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1007\/s00432-021-03767-4","volume":"148","author":"S Chen","year":"2022","unstructured":"Chen S, Wu Z, Shi F, Mai Q, Wang L, Wang F, Zhuang W, Chen X, Chen H, Xu B et al (2022) Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study. J Cancer Res Clin Oncol 148(8):2115\u20132125","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03829-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03829-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03829-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:59:34Z","timestamp":1747205974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03829-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3829"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03829-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"3 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}